DEEP PHARMA INTELLIGENCE

DEEP KNOWLEDGE GROUP

Deep Pharma Intelligence

Overview

www.deep-pharma.tech
info@deep-pharma.tech

www.dkv.global
info@dkv.global


About Deep Knowledge Group

Table of Contents

About Deep Knowledge Group	**3**
Deep Knowledge Group Structure	4
Analytical Methods and Systems Developed by Deep Knowledge Group	6
Deep Knowledge Group Longevity Industry Database	8
Overview of Big Data Analytics System and Dashboards	9
Deep Knowledge Group Coverage in Top-Tier Media	14
Comprehensive Materials for the Longevity Industry Exploring	17
Possibilities for Cooperation	**18**
About Deep Pharma Intelligence	20
Deep Pharma Intelligence — New Era in Pharma Analytics	21
AI in Drug Discovery Analytical Dashboard	22
Comprehensive Market Intelligence	23
Regular Conferences and Webinars	24
Strategic Business Consulting	25
Management Team	26
Articles, Scientific Journals and Books	27

About Deep Knowledge Group

Deep Knowledge Group is a consortium of commercial and non-profit organisations active on multiple fronts in the realm of DeepTech and Frontier Technologies (AI, Longevity, FinTech, GovTech, InvestTech), ranging from scientific research to investment, entrepreneurship, analytics, media, philanthropy and more.



Deep Knowledge Group runs several data-driven **investments and financial vehicles**

- DEEP KNOWLEDGE VENTURES
- InvestTech Platform
- LFC LONGEVITY FINANCIAL CLUB
- DeepTech and Longevity Industry Financial Advisors
- LONGEVITY CARD
- LONGEVITY CAPITAL

Deep Knowledge Group's **analytical subsidiaries** are world leaders in analytics for DeepTech and Longevity industries

- AGING ANALYTICS AGENCY
- Big Data Analytics Department
- GovTech Analytics
- FemTech Analytics
- NeuroTech Analytics
- DEEP KNOWLEDGE ANALYTICS
- SpaceTech Analytics
- DEEP PHARMA INTELLIGENCE

Deep Knowledge Philanthropy pioneers several infrastructural **social impact projects**

- DEEP KNOWLEDGE PHILANTHROPY
- 5th Industrial Revolution Institute
- LONGEVITY INTERNATIONAL
- ATLAS
- Swiss Longevity Valley
- Biogerontology Research Foundation — Prevent. Restore. Preserve.

DeepTech-Related Analytical Subsidiaries of Deep Knowledge Group

Deep Knowledge Group's analytical subsidiaries produce advanced analytics on DeepTech and frontier-technology industries, using sophisticated frameworks and algorithmic methods that combine hundreds of specifically weighted metrics and parameters to deliver insightful market intelligence, pragmatic forecasting, and tangible benchmarking.

2013

AGING ANALYTICS AGENCY

www.aginganalytics.com

2018

DEEP KNOWLEDGE ANALYTICS

www.dka.global

INNOVATION EYE

www.innovationeye.com

2019

DEEP KNOWLEDGE ANALYTICS *GOVTECH DIVISION*

www.govtech.global

NeuroTech Analytics

www.neurotech.com

2020

DEEP PHARMA INTELLIGENCE

www.deep-pharma.tech

COVID-19 ANALYTICS

www.dkv.global/covid-assessments

2021

InvestTech Advanced Solutions

www.invest-solutions.tech

SpaceTech Analytics

www.spacetech.global

FemTech Analytics

www.femtech.health

The extensive expertise in DeepTech sectors allowed us to create AI-driven Big Data Analytics System and Dashboards

Analytical Methods and Systems Developed by Deep Knowledge Group



Created frameworks as a basis for further analytical research of complex industries

Frameworks of Complex Longevity and DeepTech Industries


2013



Produced first-of-their-kind reports on Longevity and DeepTech

Fundamental Analytical Reports

2014 - 2018



Industrial and regional representation of the market development

Advanced Visualisation of DeepTech Industries

2019



Different analytical products arranged into thematic dashboards

Big Data Analytics Dashboards

2020 - 2021



Extended the number of dashboards' tools and added the embedded AI engine

AI-driven Big Data Analytics System and Dashboards

2021 - 2022

Most Comprehensive Longevity Industry Framework

We uniquely specialise in the design of multidimensional frameworks to define and precisely categorise DeepTech industries and technologies. These analytical frameworks heavily prioritise the scientific and technological features of projects and companies, and create the only reliable systematic basis for conducting effective DeepTech analysis, benchmarking, and forecasting.

Longevity Science

- Rejuvenation Biotechnology
- Basic Research on Biology of Ageing
- Geroprotectors
- Regenerative Medicine
- Nutraceuticals
- Gene Therapy

Longevity Medicine

- Personalised Diagnostics
- Personalised HALE and QALE Estimation
- Personalised Prognostics
- Personalised in Vivo and in Silico Drug Testing
- Preventive Therapies
- Participatory Medicine

AgeTech

- NeuroTech
- Cognitive Enhancement
- Smart Homes
- NextGen Mobile Apps for the Elderly
- Continuing Education
- Entertainment for the Elderly

Longevity Finance

- Longevity Index Fund
- Longevity Hedge Fund
- Longevity Stock Exchange
- AgeTech Bank
- Longevity Derivatives
- Longevity Investment Bank

Longevity Governance

- Pension Plans
- National Healthcare Budgets
- Longevity Development Strategies
- Elderly Care Programmes
- National Insurance
- Elderly Education

Longevity Ethics


- Ageism Mitigation
- Civil Participation
- Logistical Effects of Longevity
- Age-Friendly Environment
- Social Inclusivity
- Healthcare as a Basic Human Right

Deep Knowledge Group Longevity Industry Database (*Largest in the World*)

50,000 Companies	**1,000 Hubs**
20 Sectors	**10,000 Investors**

Deep Knowledge Group's first-of-its-kind **Longevity Industry Ecosystem IT-Platform** constitutes the **world's largest** Longevity industry database in the world, encompassing **50,000+ companies**, 10,000+ investors, and 1,000+ R&D hubs across **20 sectors** and **160 subsectors**, covering over **18 million data points in total**.

Deep Knowledge Group aims to create a full-scope database and frameworks for the analysis of the DeepTech Industry with an approach similar to the Longevity Industry. This goal is planned to be reached in upcoming 3-6 months.



Overview of Big Data Analytics System and Dashboards

We provide profound investment and data science insights on the private and public markets via **customised IT-Platforms and Dashboards.**


512,000+	Companies
40,000	Investors
33 million	Data Points
170	Parameters of Automated SWOT Analysis





Market Intelligence Focus

HealthTech	DeepTech	BioTech
Longevity	GovTech	Philanthropy

Deep Knowledge Group's Big Data Analytical System and Dashboards













Significant Disproportions in the Number of Companies and Data Available



*** disproportion accounts for the difference between the number of public and private companies and the amount of available relevant market intelligence**

Patterns recognition	Eliminating the disproportions	AI-driven cross-analysis

Our Unique Approach: Applying AI to Get Value From Data Disproportions





Product Value


Discrepancy Detection Within IP/Technology and Financial Domains

Defining Fair Market Position for Targeted Companies

Deriving value from the discrepancy between abundance of public equity data and scarcity of private equity data via implementation of advanced AI and data analytics techniques.

Big Data Analytics Systems and Dashboards Integrations

InvestTech Platform for Private Equity



End-to-end LegalTech solution for investors to deploy capital easily and for start-ups to fundraise and keep growing


Thematic Stock Exchange



The new specialised stock exchange reinforcing the rapidly growing industry


Big Data Analytics Systems and Dashboards

Investor Relationship Management System



Integrated contact database, analytics, reporting tools, dashboards for investor relations

IP Investment and Trading Platform



Specialised solutions for investors, start-ups, and R&D organisations commercialising intellectual property

Deep Knowledge Group Coverage in Top-Tier Media

«In May 2014 Deep Knowledge Ventures — a Hong Kong venture-capital firm specialising in regenerative medicine — broke new ground by appointing an algorithm called VITAL to its board.

VITAL makes investment recommendations by analysing huge amounts of data on the financial situation, clinical trials and intellectual property of prospective companies. Like the other five board members, the algorithm gets to vote on whether the firm makes an investment in a specific company or not.»

Yuval Noah Harari "Homo Deus: A Brief History of Tomorrow", page 322

«Deep Knowledge Ventures, a Hong Kong- based venture capital fund that invests in life sciences, cancer research, age-related diseases and regenerative medicine has appointed an artificial intelligence algorithm called VITAL (Validating Investment Tool for Advancing Life Sciences) to its board of directors.»

Klaus Schwab "The Fourth Industrial Revolution", page 149



Daily Mail
BUSINESS INSIDER
Forbes
FORTUNE
FT FINANCIAL TIMES
BBC
The Guardian
FOX NEWS channel
CNBC
CNN
DER SPIEGEL
RSI
NIKKEI ASIAN REVIEW
Esquire
The Telegraph
WELT
The Washington Times

Deep Knowledge Group's continuous, systematic internal development of advanced data science, AI and IT solutions for DeepTech analytics, predictive forecasting, and benchmarking across our investment, entrepreneurship, analytics, and philanthropic activities as the main tool for coping with the notorious complexity of DeepTech domains is well known, receiving coverage even as early as 2014 in bestselling books on the future of technology, including ***Homo Deus*** by **Yuval Noah Harari** and ***The Fourth Industrial Revolution*** by **World Economic Forum Founder and Chairman Klaus Schwab**, as well as hundreds of instances of top-tier global media coverage.

www.dkv.global/media-news

Longevity Conferences by Top-Tier Financial Corporations and Brands









INVESTING IN LONGEVITY

Longevity Industry 2022 Overview

Dmitry Kaminskiy

Deep Knowledge Group
General Partner

Davos, 25 May 2022


Longevity Financial Advisors

DEEP KNOWLEDGE GROUP


LONGEVITY CAPITAL



Comprehensive Materials for the Longevity Industry Exploring



www.longevity-book.com



www.longevity-journal.info

Possibilities for Cooperation

Longevity Financial Advisors | DEEP KNOWLEDGE VENTURES | LONGEVITY CAPITAL


- De-Risk Your DeepTech Investment Portfolio
- Order DeepTech Advisory
- Invest in Our DeepTech Products
- Get Access to Our InvestTech Platform
- Use a Longevity Banking Card

www.dkv.global/investments

AGING ANALYTICS AGENCY | DEEP KNOWLEDGE ANALYTICS | DEEP PHARMA INTELLIGENCE | InvestTech Advanced Solutions

- Use Analytics for Business and Public Administration Purposes
- Get Access to Our Big Data Analytical Dashboards
- Order Proprietary Reports

www.dkv.global/analytics



LONGEVITY INTERNATIONAL

- Get Access to Unique Full-fledged Database of All Worldwide Longevity Actors: Investors, Companies, R&D Centres, Leaders, Personalities, Influencers

www.longevity.international

LONGEVITY CHARITY | DEEP KNOWLEDGE PHILANTHROPY

- Support Our Social and Charity Projects
- Participate in Conferences with the World's Best Experts
- Obtain an Academic Sponsorship

www.deep-knowledge.org

About Deep Pharma Intelligence

Deep Pharma Intelligence — New Era in Pharma Analytics

Deep Pharma Intelligence (DPI), an analytical subsidiary of Deep Knowledge Group, is a highly specialised think tank in the area of BioTech innovation profiling, market intelligence, and BioTech development advisory. The company is dedicated to producing powerful data mining and visualisation systems, interactive analytics tools, and industry reports, offering deep technical insights, market intelligence, and strategic guidance in the high growth and significant opportunity areas.

DPI is Focusing on Three Key Activities:

Conducting Market Intelligence

Producing regular **open-access** and **proprietary reports** on the emerging topics and trends in the pharmaceutical and healthcare industries. All reports are supported by our back-end analytics systems and tools that allow to receive fresh insights and updates about opportunities and risks.



Creating Big Data Analytical Dashboards

Building a comprehensive **Big Data Analytical Dashboard** (SaaS) as a one-stop-platform for all market and business intelligence operations our customers may need, including profiling thousands of companies, market signals and trends based on tens of millions of constantly updated data points.



Producing Scientific Content


DPI provides a **full-cycle development of articles, scientific journals, and books**. We are ready to develop a detailed Requirement Specifications document, including layout of the journal, fully designed brand book, with example templates for each chapter.



AI in Drug Discovery Analytical Dashboard

AI in Drug Discovery Analytical Dashboard is a fundamental tool for strategic insights, opportunity evaluation, competitor profiling, and other purposes relevant to Pharma and BioTech decision-makers, life science investors, consulting companies, and regulatory agencies.


490	Companies
1,100	Investors
290	R&D Collaborations
120	Clinical Trials
170	Parameters of Automated SWOT Analysis



Market Intelligence Focus

- Automated SWOT Analysis
- Stock Price Forecasting
- Interactive Chart Builder
- Automized Competitive Analysis
- Financial Portfolio Constructor
- Matching Tool for Investors

Automated SWOT Analysis as a Key Tool of Deriving Value from the Data Scarcity



Key Features:

- Unlimited number of compared companies
- Entities from all industries and markets
- On-demand analytics and due diligence for one or multiple companies
- Competitive comparison of hundreds of parameters in a matter of seconds

- **Automated Comparative Competitive SWOT AI-Driven Analysis is the core solution allowing to visualise the comparison of companies based on 170 unique parameters.**
- **Based on unique logical frameworks developed over 9 years and specifically designed for selected industries.**


Comprehensive Market Intelligence

Deep Pharma Intelligence's proprietary services include **custom consulting projects based on the specific customer needs**, as well as a collection of preproduced "ready-to-use" proprietary reports, produced by our research team and covering general trends and specific action ideas and strategy insights related to the most promising business prospects (e.g. new technologies, BioTech start-ups), M&A prospects (e.g. pipeline development targets), and strategic growth ideas (trends profiling, industry overviews, etc).

Selected Open Access Reports



Artificial Intelligence for Drug Discovery Landscape Overview, Q1 2022 is an analytical report that aims to provide a comprehensive overview of the AI in drug discovery industry, clinical research, and other aspects of pharmaceutical R&D.



Cancer Vaccine Industry Landscape Overview, Q1 2022 is an analytical report created by Deep Pharma Intelligence company that focuses on a segment of cancer vaccine companies. The report describes five main cancer vaccine approaches and highlights key market players.



Landscape of Advanced Technology Companies in Pharmaceutical Industry Q4 2021 is an analytical report providing insights into the expansion of technology developers and vendors in the pharmaceutical space, as well as their increasing role in the pharmaceutical business.

Regular Conferences and Webinars

Deep Pharma Intelligence regularly holds conferences and webinars focused on specific topics in the pharmaceutical, BioTech, drug development, technology, and healthcare industries. Specialists from Deep Knowledge Group and invited business representatives provide thoughts and findings of **recent advances and trends in this market**, which are well-suited for both private and institutional investors looking for an additional enhancement to their market analytics.

Selected Conferences and Webinars



AI in Drug Discovery, Biomarker Development and Advanced R&D webinar aims to give a complete picture of the industry environment in terms of AI usage in drug discovery, clinical research, and other elements of pharmaceutical research and development. This webinar was designed to guide the hearer through what is happening in this industry right now and to potentially predict what will happen next.



Landscape of Cancer Vaccines and Research Platforms: the Cutting Edge event shares findings from a unique market study revealing R&D platforms for developing therapeutic cancer vaccines, the key players in each category, the science behind the development, and case studies illustrating the opportunities and challenges of each research strategy. The webinar hosted research and business presentations from invited industry experts.



The Rise of Advanced Technology in the Pharmaceutical Industry was a 3-day conference where specialists from Deep Knowledge Group and invited business representatives provided thoughts and findings on trends and application use cases of AI in technology, pharmaceutical, and healthcare industries; robotics in pharmaceutical research in combination with Machine Learning; and many other fascinated technologies.

Business Consulting Services

Deep Pharma Intelligence offers a comprehensive range of **consulting services**, including **market and competitor research, technology scouting and due diligence, investment landscape profiling and comprehensive analytics support for investment decision-making.**

Investment Landscape Profiling

Identifying investment trends in the pharma, BioTech, medicine, healthcare, drug development technological space, investments risk profiling based on risk tolerance, risk capacity, and risk requirements.



Technology Scouting and Due Diligence

Identifying, locating, and evaluating existing or developing technologies, products, services, and emerging trends. The service includes business, science and technology, intellectual property (IP) profiling, and potential assessment.

Market Research

Thorough market assessment within a specific industry in the field of pharma, BioTech, medicine, healthcare, drug development, AI, and other.

Competitor Research

Competitive analysis of companies, technologies, technological sectors, etc. Competitive analysis includes SWOT analysis and competitive profiling.

Management Team



Emma Brodina

Deputy Managing
Partner at DKG



Ian Inkster

Director at DPI



Stefania Saveni

Vice President
of Business Development at DPI



Andrey Savitskiy

Project Manager at DPI



Anna Maguza

Head of Analytics at DPI



Oleg Kucheriavyi


Fullstack Developer at DPI

Articles, Scientific Journals, and Books

DPI provides an full-cycle development of articles, scientific journals, and books. We are ready to develop a detailed Requirement Specifications document, including layout of the journal, complete design of the brand book, with example templates for each chapter. The final product includes:

1. **Industry overview and Top-N notable company profiles** with description of industry leaders, potential cooperation, etc.
2. **Science news and overview of current research ideas.** Includes up to five articles highlighting research dedicated to questions of fundamental science.
3. **Industry Developments.** Highlights business activity and industry developments in the selected area.
4. **Ask an Expert:** Reflections of key leaders of the industry.
5. **Investor's Handbook.** Provides readers with an analytical summary on investments and financial deals in the industry.
6. **Events digest.** Presents a digest of events in the industry. Digest includes conferences, webinars, workshops, meetings, etc.

Example of a Journal Page



November 21 | Takeda.com | Takeda Magazine

A Bayesian machine learning approach for drug target identification using diverse data types

While most researchers are hesitant about what data type to use in their models, a scientific team led by Olivier Elemento created an AI-based drug discovery platform that uses various data classes. The algorithm was named BANDIT, which stands for "Bayesian ANalysis to Determine Drug Interaction Targets." In their system, scientists combined 5 different types of data: drug efficacies, post-treatment transcriptional responses, drug structures, reported adverse effects, bioassay results and already known targets, and received around 90% of target prediction accuracy. The model also aims to address a wide range of issues in drug discovery: from target identification and compound screening to discovery of mechanisms of action (MoA) for approved but understudied drugs.
Further experiments were conducted in order to find anticancer treatments that target microtubule assembly. Using BANDIT technology, scientists discovered 14 orphan small molecules that disrupt tubule polymerization in breast cancer cells. As tumours are notorious for developing drug resistance over time, the authors also decided to check if their top-scoring molecules could overcome this barrier. Strikingly, three compounds demonstrated promising efficacy and decreased resistance to Eribulin (an FDA-approved anticancer therapeutic) from 7050-fold to 4-fold in ovarian cancer cells.
Aside from identifying targets for orphan chemicals, the model can be used to investigate mechanisms of action for effective drugs. BANDIT maps compounds based on molecular features, and drugs with analogous MoA tend to cluster. Using this approach, Elemento and colleagues discovered a previously unknown binding partner for ONC201 – a small molecule that participates in clinical trials for advanced cancers. The molecule turned out to be a ligand of the dopamine receptor DRD2, which prompted the launch of its clinical trials to treat pheochromocytomas, neuroendocrine tumours that express high levels of this receptor.

Olivier Elemento, *Professor of Physiology and Biophysics at Weill Cornell Medical College*

"In this paper, we showed for the first time that integrating diverse data types using Bayesian AI can dramatically enhance our ability to predict the mechanisms of action of small molecules - a very difficult problem otherwise. This, in turn, led to a number of applications - from finding the true protein target of a small molecule and designing a clinical trial accordingly, to finding new molecules that unexpectedly shows antimicrotubule activity"

AlphaFold – A Major Step Towards Computational Proteomics

For many decades, exploring the tertiary protein structure was a scientific nightmare: years spent on tiresome work to build a model did not always result in success. Until July 2021, a software that could generate an accurate 3D model from the amino acid sequence was just a dream, but recently it became reality – when a team of 34 scientists from DeepMind, Alphabet Inc's artificial intelligence subsidiary, published a groundbreaking paper in Nature, describing the updated version of AlphaFold technology and providing open-access code on GitHub.
AlphaFold's story began in 2018, when the first version of the program competed in the Critical Assessment of Protein Structure Prediction (CASP), outperforming all other methods for predicting protein structures. Even back then, the AI software was regarded as a significant achievement; however, when the second version debuted in the same blind challenge CASP in 2020, it was hailed as an "amazing" and transformative tool for structural biology.
The deep learning neural network was trained using experimentally determined data from Protein Database (PDB). In its models, AlphaFold provides exceptional atomic accuracy of 0.96 Å, for comparison, the width of the atom is 1.4 Å. For predictions, the model employs physical and geometric inductive biases, evolutionary information derived from Multiple Sequence Alignment and pairwise features. It is built from Evoformers – blocks that shape a structural hypothesis, continuously and iteratively refining it throughout the whole system to provide maximum accuracy. AlphaFold can generate not only simple protein structures but also homomeric and heteromeric structures, as well as domains that fold in the presence of specific factors, such as a heme group.

Although AlphaFold does not completely solve the problem of protein folding, it greatly affects the future of biology. Professionals think that it will be used as a search model for X-ray crystallography, replace de novo domain modelling in NMR and accelerate large structure solutions by cryo-EM. One of the global scientific goals that AlphaFold can help to achieve is the discovery of the structural proteome of all sequenced organisms.

Crowdsourced mapping of unexplored target space of kinase inhibitors

The laboratory search of target-inhibitor interactions helped scientists to reach and control the work of 11% of the proteome. This gave us an opportunity to fight diseases never considered to be treatable in the past, manipulating small molecular gears in the complex system of the human body. Yet now, when progress made by various computational technologies is gaining momentum, the experimental approach in target discovery still slows down the whole chain of drug development. Given the number of proteins and genes implicated in disease processes, screening all of them is challenging. Anna Cichonska, Balaguru Ravikumar, and Robert J. Allaway are trying to break the deadlock by leveraging "crowd wisdom". Their aim is to develop a state-of-art machine learning algorithm capable of predicting target inhibitors with greater accuracy than any other technology. To reach the goal, the scientific group established the IDG-DREAM Drug-Kinase Binding Prediction Challenge which attracted more than 200 active participants.
The challenge focused on the space of understudied kinases – understudied enzymes with solid assay data but no small chemical inhibitors. All results were compared to the baseline kernel regression model, which is currently one of the best ML techniques for identifying compound-target potencies. Participants' models were trained using open-access data from DrugTargetCommons (DTC), which contained 95 inhibitory compounds and 295 kinases in total. Five of the top-performing teams used surprisingly different ML approaches to solve the problem: deep learning, graph convolutional networks, gradient boosting decision trees, kernel learning, and regularized regression.

Epigenetic Target Fishing with Accurate Machine Learning Models

In the 1990s, Robin Holliday defined epigenetics as a branch of biological sciences that studies mechanisms of temporal and spatial control of gene activity. Since then, researchers have discovered a number of links between pathogenic processes and epigenetic pathways, opening up new opportunities for drug development.
Norberto Sánchez-Cruz and José L. Medina-Franco developed a machine learning model that predicts epigenetic targets using molecular fingerprints, cheminformatic attributes that contain information about a compound structure. Researchers first linked various ML algorithms with molecular fingerprints and validated the pairs on small subsets of data and then chose the best combinations. The SVM (Support Vector Machines) method together with Morgan or RDK fingerprints showed the most promising outcomes with two winning combinations later blended into one consensus model. The consensus model was validated on a large-scale multi-target screening, involving 26,318 molecules and 55 epigenetic proteins. Predictions were compared to screening results of already existing tools HitPick-V2, SEA, PPB2, and SwissTargetPrediction, demonstrating more accurate epigenetic target predictions by the new model. The algorithm is available as a free web application at www.epigenetictargetprofiler.com.

Scientific Journal Team



Dr. Andrii Buvailo is a pharmaceutical industry analyst and writer, focusing on emerging companies (start-ups), technologies, and trends in drug discovery, as well as R&D outsourcing. His articles were published on Forbes.com, and market research reports were referenced by some of the leading life science organisations. **Dr. Buvailo** is a **co-founder of** www.BiopharmaTrend.com and also one of **technical and marketing executives at Enamine**, a global chemical CRO and supplier of chemicals for drug discovery.

Diana Vasyliuk is a **writer in DPI's scientific journals**. She holds a bachelor's degree in biology from Taras Shevchenko National University of Kyiv (Ukraine). Currently, she is working on her **master's degree at the University of British Columbia (Canada)** where she also did an internship. Additionally, Diana is training in Merck Group.





Julia Motrenko is a **writer and associate editor in DPI's scientific journals**. She holds a bachelor's degree in cell biology from Taras Shevchenko National University of Kyiv (Ukraine). Currently, she is working on her **master's in Business and Bioentrepreneurship at Copenhagen Business School** (Denmark). During her scientific career, Julia received internship training at the University of Tokyo (Japan) and Harvard Medical School (USA).

Press about Deep Pharma Intelligence and Its Founding Partners

Bloomberg	‘**Deep Pharma Intelligence** conducted and released today (2 December 2020) an independent analysis regarding Citron Research and Muddy Waters short-sell campaign against Israeli Nasdaq traded company “Nanox”’.
Forbes	‘As noted by **Dr. Andrii Buvailo, Director at Deep Pharma Intelligence**: “Some of the leading emerging players in the pharmaceutical AI race include US-based Deep Genomics, Healx and Recursion Pharmaceuticals as well as Hong Kong-based Insilico Medicine”’.
FT FINANCIAL TIMES	‘Despite the recent hype, there is a lack of AI specialists and “promising” drug discovery AI-start-ups, according to **Deep Knowledge Analytics’.**
The Guardian	‘Britain has all the required resources, as well as industrial and governmental will, to become a global hub for the technology by 2022, according to analysis by the Big Innovation Centre and **Deep Knowledge Analytics’.**
Forbes	‘By 2022, the UK will be a global hub for blockchain technologies and the crypto economy. That is the claim of a new report from the Big Innovation Centre and **Deep Knowledge Analytics**, released last month’.
MarketWatch	‘If we were to follow the logic of these Short Sellers Reports to their fullest extent, it could be concluded that all innovative, DeepTech-driven companies working on something fundamentally new and disruptive may be easily accused in fraud,” adds Co-founder at **Deep Knowledge Analytics Mr. Dmitry Kaminskiy’.**

Deep Knowledge Group

www.dkv.global | info@dkv.global

Deep Pharma Intelligence

www.deep-pharma.tech | info@deep-pharma.tech

DEEP PHARMA INTELLIGENCE LIMITED

UK Company Registration Number: 12987888,
63-66 Hatton Garden, 5th Floor,
Suite 23, London, England, EC1N 8LE